Nathan Quaderer, DO
Family Medicine · Grand Blanc, MINPI 1760971451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $775, 2.6 times the $301 reported in 2019.
Across 92 payments — averaging $28.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$347
- Novo Nordisk$331
- Johnson & Johnson$294
- Lilly USA, LLC$256
- Amgen$213
- Pfizer$182
- plus $995 from 27 others
What the payments were for
- Food & beverage$2,620100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $347 |
| Novo Nordisk | 15 | $331 |
| Johnson & Johnson | 4 | $294 |
| Lilly USA, LLC | 12 | $256 |
| Amgen | 9 | $213 |
| Pfizer | 8 | $182 |
| Jazz Pharmaceuticals Inc. | 2 | $146 |
| Neurocrine Biosciences, Inc. | 1 | $102 |
| Gilead | 1 | $80 |
| AstraZeneca | 1 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Lundbeck LLC | 2 | $43 |
| Exact Sciences | 2 | $42 |
| Cranial Technologies, Inc | 3 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Globus Medical | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
| GSK | 1 | $20 |
| Photonicare Inc | 1 | $19 |
| Indivior Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Novartis | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Abbott | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,620 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $84,868 |
| JanuviaSitagliptin Phosphate | 45 | $51,539 |
| EliquisApixaban | 35 | $42,707 |
| TrulicityDulaglutide | 39 | $36,999 |
| MounjaroTirzepatide | 33 | $36,307 |
| JardianceEmpagliflozin | 31 | $36,033 |
| XareltoRivaroxaban | 37 | $35,152 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,338 |
| InvokanaCanagliflozin | 13 | $8,511 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $6,903 |
| Atorvastatin Calcium | 379 | $6,197 |
| MultaqDronedarone Hcl | 12 | $4,591 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,459 |
| Rosuvastatin Calcium | 84 | $1,994 |
| Losartan Potassium | 145 | $1,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $331 | $84,86894 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $256 | $73,30772 claims |
| MerckJanuvia | $18 | $51,53945 claims |
| Johnson & JohnsonXarelto, Invokana | $294 | $43,66350 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $23 | $42,93746 claims |
| PfizerEliquis | $182 | $42,70735 claims |
| GSKTrelegy Ellipta | $20 | $14,33823 claims |
| AbbVieArmour Thyroid | $347 | $1,37415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Grand Blanc
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.